News for Keros Therapeutics, Inc. (KROS)

Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1's Disruptive and Self-Serving Campaign Stan

BofA's analyst, Jason Zemansky, has adjusted the price target for Keros Therapeutics (KROS) from $33 to $32, maintaining a Buy rating on the company's stock. De

PR NewswireAUSTIN, Texas, May 21, 2025 ADAR1 Urges Board to Release Strategic Review Results Before, Not After, Annual MeetingAUSTIN, Texas, May 21, 2025 /

ADAR1 Capital Management, holding 13.3% of Keros Therapeutics (KROS) shares, has publicized that Institutional Shareholder Services, a reputable proxy advisory

Keros (KROS) is urging its shareholders to vote in favor of its three proposed directors, Mary Ann Gray, Ph.D., Ran Nussbaum, and Alpna Seth, Ph.D., at the upco

Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting ”œFOR” Each of the

PR NewswireAUSTIN, Texas, May 12, 2025 AUSTIN, Texas, May 12, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), t

ADAR1 Capital Management, which holds about 13.3% of Keros Therapeutics (KROS) shares, has released a presentation detailing their reasons for opposing the re-e

ADAR1 Capital Management, holding a 13.3% stake, opposes the re-election of two Keros Therapeutics (KROS) board members. The decision will be finalized

On May 12, 2025, Scotiabank analyst Greg Harrison released an update on Keros Therapeutics (KROS), maintaining the "Sector Outperform" rating for the company. T

**media[619777]**

ADAR1 Capital Management challenges Keros Therapeutics on capital allocation and board decisions. Read more here.

PR NewswireAUSTIN, Texas, May 8, 2025 Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna SethAUSTIN, Texas, May 8, 2025 /P

Keros Therapeutics (KROS) delivered earnings and revenue surprises of 36,300% and 149.64%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (”œKeros” or the ”œCompany”) ( KROS), a clinical-stage biopharmaceutical com

Net Income: Achieved a net income of $148.5 million, a significant turnaround from a net loss of $43.1 million in the same quarter last year.Revenue: Total rev

Keros Therapeutics (KROS) reported significant financial improvements in the first quarter, with revenue reaching $211.25 million. This performance led to a net

U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 4% on Thursday. The Dow traded down 4.18% to 38,910.71 while the NA...

U.S. stocks were lower, with the Dow Jones index dipping over 800 points on Thursday. Shares of PriceSmart, Inc. PSMT rose sharply during Thursday's session fo...